Immunexpress Unveils Promising Research at SCCM 2025 on Sepsis Detection

Introduction

Immunexpress, a molecular diagnostics pioneer, is making waves at the Society of Critical Care Medicine (SCCM) Critical Care Congress taking place from February 23 to 25, 2025, in Orlando, Florida. With an impressive portfolio aimed at enhancing sepsis outcomes, the company is set to present critical data that underscores its commitment to addressing a global health concern that claims nearly 11 million lives each year.

A Focus on Sepsis

Sepsis is often termed the silent killer, as it can escalate rapidly, leading to severe complications if not diagnosed early. Immunexpress aims to combat this issue through its innovative product, SeptiCyte RAPID. This state-of-the-art test utilizes reverse transcription polymerase chain reaction (RT-PCR) to measure immune response gene expression in whole blood samples, aiding medical professionals in distinguishing between infection-positive sepsis and other inflammatory conditions.

Groundbreaking Presentations

Immunexpress’s Chief Medical Officer, Dr. Roy Davis, will kick off presentations with a talk titled “SeptiCyte RAPID performance is not affected by different sites of primary infection in sepsis.” This presentation highlights data from 378 patients across 10 hospitals in the U.S. and Europe. Findings reveal that SeptiCyte RAPID can effectively differentiate sepsis from systemic inflammatory responses, regardless of where the primary infection originates. This functionality is crucial, as different sites can alter the response to treatment and the overall outcomes for patients.

Following this, on February 25, a second presentation titled “Diagnosing Pediatric Sepsis with SeptiCyte RAPID Host Gene Expression” will delve into the effectiveness of SeptiCyte RAPID in children. This research was conducted on four patient cohorts at two pediatric hospitals in the U.S. and Australia, focusing on critically ill children aged between one month and 18 years. The results point towards a strong capability of SeptiCyte RAPID to accurately differentiate sepsis from SIRS in young patients—a demographic often overlooked in sepsis research.

Interactive Engagement at the Congress

Immunexpress is not just presenting data; they are also engaging attendees through an interactive booth from February 23 to 25. Booth #417 will showcase SeptiCyte RAPID in action, and participants can embark on a unique